Multiple Myeloma Advances: Access Eliminates Racial Disparities, Transplants Show Long-Term Remission
A Cleveland Clinic study found no racial survival disparities in multiple myeloma when patients have equal access to modern therapies. Clinical cases demonstrate long-term remission with second stem cell transplants and targeted agents like daratumumab.
Recent research and clinical cases underscore significant advances in multiple myeloma treatment, with studies demonstrating that equal access to modern therapies eliminates survival disparities between Black and white patients, and new treatment protocols achieving long-term remission.
A retrospective cohort study of 1,230 multiple myeloma patients diagnosed between 2017 and 2023 across the Cleveland Clinic system found no significant differences in access to triplet or quadruplet therapies between Black and white patients, and no difference in five-year overall survival. The study, presented at the 2026 American Society of Clinical Oncology Annual Meeting, reported that 57.5% of patients received triplet or quadruplet therapy within one year of diagnosis, with similar rates for white (56.6%) and Black (58.9%) patients. Kaplan-Meier estimates showed a 62.1% five-year overall survival probability for the entire cohort, with Black patients not having a higher risk of death compared with white patients after adjustment for clinical and socioeconomic factors.
The findings suggest that differences in multiple myeloma outcomes may be driven more by differences in access to care than by disease biology. When obstacles to timely diagnosis and treatment are overcome, outcomes are comparable across racial groups.
Clinical cases from India illustrate the effectiveness of advanced myeloma therapies, including second autologous stem cell transplants and targeted agents. A 77-year-old woman with relapsed myeloma achieved complete remission after a second autologous stem cell transplant, having initially been treated with a VRD regimen (bortezomib, lenalidomide, dexamethasone) and maintenance therapy. At relapse, she received a daratumumab-based four-drug induction regimen followed by high-dose chemotherapy and a second transplant. She now continues maintenance therapy with lenalidomide and denosumab.
Another case involved a 70-year-old man diagnosed in 1999 with IgG Kappa multiple myeloma, who underwent two autologous stem cell transplants over more than two decades and remains disease-free. His treatment evolved from the VAD chemotherapy protocol to targeted regimens including bortezomib, lenalidomide, and dexamethasone.
Key advances in myeloma management include the replacement of conventional chemotherapy with targeted therapies such as daratumumab, a CD38 monoclonal antibody, in initial treatment regimens. Maintenance therapy with agents like zoledronic acid or denosumab helps prevent skeletal complications. Second autologous stem cell transplants are now considered safe and effective when performed after a gap of more than three years. Newer drugs like carfilzomib and bispecific antibodies such as teclistamab are achieving prolonged disease control, and CAR-T cell therapy is expected to further improve outcomes in relapsed and refractory myeloma.